New York, January 21, 2026, 11:46 EST — Regular session
- Shares of Thermo Fisher rose roughly 1.9% in late morning trading, outperforming the broader market.
- Australia’s ACCC launched a Phase 1 review into Thermo’s proposed Clario acquisition, with a decision due by March 2
- Investors are eyeing the January 29 results for clues on 2026 demand and when deals might close
Thermo Fisher Scientific Inc NYSE:TMO shares climbed roughly 1.9% to $630.48 Wednesday, outpacing the broader market as investors digested new regulatory developments around its planned Clario acquisition. The stock hit an intraday high of $631.25 earlier in the session.
The Australian Competition and Consumer Commission (ACCC) has launched a Phase 1 review — its preliminary check — of Thermo Fisher’s planned acquisition of Clario, the regulator’s acquisitions register shows. The ACCC marked the deal as “under assessment” and gave itself a deadline of March 2 for a decision. ACCC
Thermo’s next big event is just around the corner. The company plans to report its fourth-quarter and full-year 2025 results before the U.S. market opens on Thursday, Jan. 29. A conference call is set for 8:30 a.m. ET that day.
In October, Thermo struck a deal to acquire privately held Clario for $8.875 billion in cash at closing, plus additional payments based on future results. Clario specializes in clinical trial “endpoint” data services—the key metrics used to determine a treatment’s effectiveness and safety. Thermo’s CEO Marc Casper described Clario as “an outstanding strategic fit” at the time. Thermo Fisher Scientific
Thermo’s jump happened amid a wider rally in risk assets. The SPDR S&P 500 ETF Trust gained roughly 1.0%, Invesco QQQ climbed about 1.3%, and fellow life-science tools names Danaher, Agilent, and Repligen also pushed higher.
The New York Stock Exchange filed a Form 25 to delist Thermo Fisher’s 3.200% senior notes due 2026, according to a separate regulatory filing. This form removes the security from exchange listing but doesn’t affect Thermo’s common stock.
Traders are focused on two key factors that could swing the shares sharply: first, whether management boosts projections for biopharma and biotech demand through 2026, and second, if regulators maintain a smooth approval process for the Clario deal.
The risk lies in regulatory reviews dragging on or imposing conditions, while Thermo’s Jan. 29 outlook could disappoint if customers hold back on lab and clinical budgets. Either scenario might turn Wednesday’s jump into nothing more than a fleeting spike.
Coming up, the earnings report and call are set for Jan. 29. Then, on March 2, the ACCC hits its end-of-determination window for the initial review of the Clario deal.
